Menu
Back to Journals » Drug Design, Development and Therapy » Volume 15
Original Research
Pristimerin Protects Against OVX-Mediated Bone Loss by Attenuating Osteoclast Formation and Activity via Inhibition of RANKL-Mediated Activation of NF-κB and ERK Signaling Pathways
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 5,065 | Dovepress* | 4,456+ | 964 | 5,420 | |
| PubMed Central* | 609 | 194 | 803 | ||
| Totals | 5,065 | 1,158 | 6,223 | ||
| *Since 7 January 2021 | |||||
View citations on PubMed Central and Google Scholar